References
- Advani, R., Fisher, G.A., Lum, B.L., Hausdorff, J., Halsey, J., Litchman, M., Sikic, B.I. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res. 7, 1221–9.
- Borst, P., Evers, R., Kool, M., Wijnholds, J. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 92, 1295–302.
- Bosch, I., Dunussi-Joannopoulos, K., Wu, R.L., Furlong, S.T., Croop, J. (1997). Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry. 36, 5685–94.
- Coley, H.M. (2008). Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 34, 378–90.
- Eckford, P.D., Sharom, F.J. (2008). Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry. 47, 13686–98.
- Elamanchili, P., McEachern, C., Burt, H. (2008). Reversal of multidrug resistance by methoxypolyethylene glycol-block- polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function. J Pharm Sci. 98, 945–58.
- Goren, D., Horowitz, A.T., Tzemach, D., Tarshish, M., Zalipsky, S., Gabizon, A. (2000). Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res. 6, 1949–57.
- Jabr-Milane, L.S., van Vlerken, L.E., Yadav, S., Amiji, M.M. (2008). Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 34, 592–602.
- Kono, K., Igawa, T., Takagishi, T. (1997). Cytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivative. Biochim Biophys Acta. 1325, 143–54.
- Lee, M.K., Lim, S.J., Kim, C.K. (2007). Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials. 28, 2137–46.
- Mamot, C., Drummond, D.C., Hong, K., Kirpotin, D.B., Park, J.W. (2003). Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat. 6, 271–9.
- Michieli, M., Damiani, D., Ermacora, A., Masolini, P., Michelutti, A., Michelutti, T., Russo, D., Pea, F., Baccarani, M. (1999). Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br J Haematol. 106, 92–99.
- Mohri, M., Nitta, H., Yamashita, J. (2000). Expression of multidrug resistance-associated protein (MRP) in human gliomas. J Neurooncol. 49, 105–15.
- Romsicki, Y., Sharom, F.J. (1999). The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry. 38, 6887–96.
- Sharom, F.J. (2008). ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 9, 105–27.
- Shukla, S., Wu, C.P., Ambudkar, S.V. (2008). Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol. 4, 205–23.
- Slepushkin, V.A., Simoes, S., Dazin, P., Newman, M.S., Guo, L.S., Pedroso de Lima, M.C., Duzgunes, N. (1997). Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J Biol Chem. 272, 2382–8.
- Thews, O., Gassner, B., Kelleher, D.K., Gekle, M. (2008). Activity of drug efflux transporters in tumor cells under hypoxic conditions. Adv Exp Med Biol. 614, 157–64.
- Thierry, A.R., Dritschilo, A., Rahman, A. (1992). Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem Biophys Res Commun. 187, 1098–105.
- Thierry, A.R., Vige, D., Coughlin, S.S., Belli, J.A., Dritschilo, A., Rahman, A. (1993). Modulation of doxorubicin resistance in multidrug- resistant cells by liposomes. FASEB J. 7, 572–9.
- Yu, G., Ahmad, S., Aquino, A., Fairchild, C.R., Trepel, J.B., Ohno, S., Suzuki, K., Tsuruo, T., Cowan, K.H., Glazer, R.I. (1991). Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun. 3, 181–9.